FDA is ridding the market of single-ingredient oxycodone capsules that are being distributed without an FDA-approved application.
Raleigh-based Kerr Drug has promoted Mark J. Gregory, RPh, to senior vice president of store operations.
Diplomat Specialty Pharmacy has promoted Atheer Kaddis, PharmD, to senior vice president of sales and marketing.
FDA has approved mirabegron (Myrbetriq, Astellas Pharma US, Inc.) to treat adults with overactive bladder, a condition in which the bladder muscle cannot be controlled, squeezes too often, or squeezes without warning.
Today, the U.S. Supreme Court upheld the Affordable Care Act as constitutional, including its individual mandate requiring all Americans to purchase health insurance.
FDA has approved lorcaserin (Belviq, Arena Pharmaceuticals and Eisai) as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients who are overweight or obese and have at least one weight-related comorbid condition. It is the first prescription weight-loss treatment approved by FDA in 13 years.
The University of Southern California School of Pharmacy has received the largest grant the school has ever received, for a massive medication adherence project.
FDA issued a complete response letter for a New Drug Application for apixaban (Eliquis, Bristol-Myers Squibb) for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.
The Kentucky Pharmacists Association has named Joseph L. Fink III, professor of pharmacy law and policy at the University of Kentucky College of Pharmacy, as Professor of Leadership.
FDA issued a complete response letter regarding a supplemental New Drug Application for rivaroxaban (Xarelto, Janssen Research & Development) for the reduction of the risk of secondary cardiovascular events in patients with acute coronary syndrome.